The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer

Charles H. Yang, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Inflammatory breast cancer is a rare but lethal form of locally advanced breast cancer. Despite improvements in survival with the advent of multidisciplinary treatment regimens, 5-year survival rates remain disappointing, at approximately 30%. Numerous molecular markers have been investigated for their potential as useful prognostic and predictive markers of treatment response that would impact on the management of inflammatory breast cancer. This review discusses the current status of p53 mutations both as a prognostic marker and as a potential target for directed therapies.

Original languageEnglish (US)
Pages (from-to)247-255
Number of pages9
JournalFuture Oncology
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2006

Keywords

  • Advexin®
  • Gene therapy
  • Inflammatory breast cancer
  • PRIMA-1
  • Prognostic factor
  • Small molecule activator
  • p53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer'. Together they form a unique fingerprint.

Cite this